PUBLISHED2 016 Cardiovascular Services OUTCOMES OUTCOMES OCHSNER Patient referrals, transfers and consults are critically important, and we want to make it easy for referring providers and their staff. To refer your patient for a clinic appointment, call our Clinic Concierge at 855.312.4190. Ochsner’s longstanding tradition of bringing physicians together to improve health outcomes continues today. Our goals are to work together with our referring providers to serve the needs of patients and to provide coordinated treatment through partnerships that put patients first. We have automated physician-to-physician patient care summaries for hospital encounters and enhanced the patient experience by giving patients the ability to schedule appointments online.
Close coordination and collaboration begin with transparency and access to the data you need to make informed decisions when advising your patients about care options. OchsnerOutcomes, a compilation of clinical data, represents only part of our efforts to better define the quality of Ochsner’s care and to share that information with you.
Trusted, independent organizations give the highest marks to Ochsner’s quality. Ochsner Medical Center was the only healthcare institution in Louisiana to receive Warner L. Thomas national rankings in six specialties from U.S. News & World Report for 2015–2016. President & Chief Executive Officer Additionally, CareChex® named Ochsner Medical Center, Ochsner Baptist, a Campus Ochsner Health System of Ochsner Medical Center and Ochsner Medical Center – West Bank Campus among the top 10% in the nation in 17 different specialties and, for the fourth year in a row, Ochsner was named #1 in the country for liver transplant. Ochsner was also recognized, again for the fourth year in a row, as one of “100 Great Hospitals in America,” by Becker’s Hospital Review.
Additionally, Ochsner Health System was named an honoree for the 2015 American Medical Group Association (AMGA) Acclaim Award. Among just four organizations nationwide to receive this recognition, Ochsner was acknowledged for our work to measurably improve quality and value of care, improve patient experience and outcomes, improve population health and promote continuous learning and innovation.
Ochsner is the first hospital in the United States – and perhaps even the globe – to partner with Apple and Epic to create a platform that can directly affect patient care in real time. Robert I. Hart, MD We are utilizing the Apple Watch as an agent for behavioral change for patients with EVP & Chief Medical Officer chronic disease, starting with patients who have uncontrolled high blood pressure. Ochsner Health System Ochsner consistently earns the respect of independent evaluators. We do not rest on these achievements, but use them as a benchmark to continuously improve. We will continue to share the data you need to care for your patients, provide services you may not have in your community and develop the collaborative relationships essential to ensuring the best outcomes for every patient, every time.
Table of Contents
Letter from the Chairman ...... 6 John Ochsner Heart & Vascular Institute ...... 8 Advanced Heart Failure ...... 11 Heart Transplant ...... 12 Left Ventricular Assist Device (LVAD) Implantation . . . 16 Patient Survival After LVAD ...... 18 Pulmonary Hypertension ...... 20 Electrophysiology ...... 23 Interventional Cardiology ...... 26 Structural Heart and Valve Program ...... 32 Transcatheter Aortic Valve Replacement . . . . . 34 Adult Congenital Heart Disease Program . . . . 36 Noninvasive Cardiovascular Imaging ...... 39 Preventive Medicine and Cardiac Wellness . . . . . 40 Patient Experience ...... 48 Research ...... 52 Clinical Trials ...... 53 Publications ...... 57 Physician Team ...... 68 Contact Information and Locations ...... 69 About Ochsner Health System ...... 70 Letter from the Chairman
New solutions for chronic and To serve even more patients, we now complex cardiovascular problems offer same-day access and convenient online appointment scheduling. Our The John Ochsner Heart & Vascular patients have full access to their medical Institute (JOHVI) at Ochsner Medical records and can review all test results to Center diagnoses and treats patients maximize transparency. We are currently using the most advanced technologies developing novel programs for repairing and outstanding subspecialty physician failing coronary stents (brachytherapy), expertise. As demonstrated in this implanting leadless pacemakers, repairing report, this translates to outstanding aortic aneurysms with customizable grafts Christopher J. White outcomes for our patients. We’ve and preventing strokes without surgery MD, FSCAI, FACC, FAHA, FESC established a national and international by placing carotid stents. We remain Professor and Chairman of Medicine reputation for excellence in patient a national leader in treating patients The Ochsner Clinical School, care and innovation in technology and with advanced heart failure, and we University of Queensland treatments. Over the years, we have been are a second-opinion center for complex System Chairman of recognized by U.S. News & World Report, cardiovascular conditions. We are excited Cardiovascular Diseases CareChex® and Healthgrades® for our about all the potential benefits we will Medical Director, John Ochsner heart and vascular achievements. continue to offer patients throughout Heart and Vascular Institute the Gulf South. at Ochsner Medical Center Ochsner is the first and only medical center in our region to perform heart transplants, At JOHVI, we are eager to help our and the only center in Louisiana to offer referring physicians manage their the artificial heart and left ventricular assist patients’ most challenging diagnoses devices (LVADs). and treatments. Through our advanced cardiovascular services, we strive to We were the first to perform heart valve restore patients’ health and improve replacement without surgery, and we their quality of life. continue to rank nationally with our high volume and low complication rates. We hope to become your trusted CARDIOVASCULAR SERVICES CARDIOVASCULAR
Our arrhythmia physicians offer new and partner in delivering the best possible | effective ablation procedures for ventricular cardiovascular care to your patients. tachycardia and atrial fibrillation. We offer the only Adult Congenital Heart Disease For information about the John Ochsner Program in the region, which serves adults Heart and Vascular Institute, visit us
OUTCOMES who were diagnosed and treated for birth online at ochsner.org/heart or contact defects of the heart as infants or children. us by phone at 888.317.3717. We look We are constantly looking for new ways forward to hearing from you. to help our patients manage complex OCHSNER or ongoing cardiovascular problems. 6 JOHN OCHSNER HEART & VASCULAR INSTITUTE
7 John Ochsner Heart & Vascular Institute
The John Ochsner Heart & Vascular Institute offers state-of-the art diagnostic and leading-edge therapies for adult and pediatric cardiology patients in a program that is ranked among the top in the nation. We have a team of experts available in:
• Advanced Heart Failure and Overview of Subspecialties Cardiac Transplantation with Volume: • Adult Congenital Heart Disease • Arrhythmia and Heart Advanced Heart Failure and Cardiac Rhythm Disorders Transplantation • Cardiac PET Imaging • Implanted Mechanical Assist Devices – 49 patients • Cardiovascular MRI and CTA Imaging Services • Heart Transplants – The only heart transplant center in Louisiana, performing • Consultative Cardiology 29 heart transplants in 2015 and more • Heart and Vascular Surgery than 900 throughout the history of the Ochsner heart transplant program
CARDIOVASCULAR SERVICES CARDIOVASCULAR • Interventional Cardiology
| • Nonsurgical Heart Valve Consultative Cardiology Replacement and Repair • Conducted more than 12,000 clinic • Pediatric Cardiology visits annually and interpreted more than 74,000 EKGs annually for the OUTCOMES • Pulmonary Hypertension Ochsner system • Stroke Prevention and Carotid Stents
OCHSNER • Vascular Medicine
8 Electrophysiology Cardiovascular Research • Device Clinic Volume – More than • Mor e than 85 active cardiovascular 4,500 device clinic assessments clinical research trials for investigational Ochsner is the only performed in 2015 therapies not available at other health systems heart transplant center • 203 radiofrequency ablations for
patients with A-fib performed in 2015 in Louisiana, performing JOHN OCHSNER HEART & VASCULAR INSTITUTE Noninvasive Cardiovascular Imaging 29 heart transplants Interventional Cardiology • Annually perform more than 24,000 echo stress tests in 2015 and more than • Nearly 5,000 procedures performed in the cardiac catheterization laboratory • Annually perform more than 900 throughout the history 1,000 cardiac PET scans of the Ochsner heart Heart Valve Program • Annually perform more than transplant program. • T ranscatheter Aortic Valve Replacement 5,400 vascular ultrasounds through (TAVR) – 150 cases in 2015 and more the Vascular Medicine department than 450 cases since 2011 • Annually perform more than • Minimally invasive mitral valve repair 325 endovenous laser therapy (EVLT)/sclerotherapy procedures • Annually perform more than 400 cardiac MRI tests that support referrals from the entire Louisiana region 9 10 OCHSNEROUTCOMES | CARDIOVASCULAR SERVICES Advanced Heart Failure
The Advanced Heart Failure Clinic is the first stop to better health through the John L. Ochsner Heart & Vascular Institute.
In addition to accessing world-class Our comprehensive services within the Heart failure affects nearly advanced heart failure physicians, our Advanced Heart Failure Clinic include specialized clinic offers a wealth of clinical evaluation, management, monitoring 5 million people in the support including patient education and and education of: United States and is one ongoing monitoring to improve quality of • Valvular function life and prevention of avoidable hospital of the most frequent admissions. In the event more aggressive • Left ventricular systolic and reasons for hospitalization. or complex services are needed, our diastolic function clinic seamlessly coordinates with our Although it can lead to • Lab work integrated group of physician specialists serious disability, or even in electrophysiology, cardiovascular • Arrhythmias and conduction death in some patients, surgery and noninvasive imaging to abnormalities meet the needs of patients. it is possible to control your • Medication management heart failure and avoid • Pulmonary hypertension many of its complications. • Cardiomiopathy (HF) • Amyloidosis ADVANCED HEART FAILURE
11 ADVANCED HEART FAILURE Heart Transplant
Heart transplant patients at Ochsner have three-year survival rates higher than the national average. In 2015, the three-year survival rate was 84.6 percent, compared to 84.2 percent nationally.
Ochsner Heart Transplant 1-Year Adult Patient Survival Hazard Ratio Comparison with Other Programs Ochsner Medical Center Program Volume for Transplants, 7/1/2012–12/31/2014
LAOF | Other Programs
5.0
Worse CARDIOVASCULAR SERVICES CARDIOVASCULAR
2.0 |
1.0
0.5 The data reported here were prepared by the
OUTCOMES Better Scientific Registry of Transplant Recipients (SRTR) Estimated Hazard Ratio Hazard Estimated under contract with the Health Resources and 0.2 Services Administration (HRSA). Based on data available as of October 31, 2015. Publication date December 2015. OCHSNER 1 3 10 30 100 300 12 Program Volume Jamie Napolitano, Heart Transplant Patient
When Jamie Napolitano was 3 months old, she was diagnosed with cardiomyopathy, a disease of the heart muscle. Her parents were told that she would probably not live past the age of 2. Despite their daughter’s prognosis, Napolitano’s parents allowed her to live like a “normal” child and she did not feel the effects of heart disease until she experienced a heart attack at age 19. Her medication regimen became more intense as her symptoms took a toll on her physical and emotional well-being. A few years later, Napolitano’s heart was functioning at about 20 percent, and she was told ADVANCED HEART FAILURE she would need a new heart. On January 1, 2009, she underwent a heart transplant at Ochsner. Since her transplant, she has run in four half-marathons. In addition to spending time with her family, Napolitano volunteers for Donate Life Louisiana and the American Heart Association. Napolitano is grateful that her donor, her hero, said yes to the gift of life.
13 14 OCHSNEROUTCOMES | CARDIOVASCULAR SERVICES Ochsner’s Cardiomyopathy and Heart Transplant Program is the largest Medicare-approved heart transplant program in Louisiana, performing over 20 heart transplants per year. It is also Louisiana’s only pediatric heart transplant program.
Ochsner Heart Transplant 3-Year Adult Patient Survival Hazard Ratio Comparison with Other Programs Ochsner Medical Center Program Volume for Transplants, 1/1/2010–6/30/2012
LAOF | Other Programs
5.0
Worse ADVANCED HEART FAILURE 2.0
1.0
0.5 The data reported here were prepared by the Better Scientific Registry of Transplant Recipients (SRTR) Estimated Hazard Ratio Hazard Estimated under contract with the Health Resources and 0.2 Services Administration (HRSA). Based on data available as of October 31, 2015. Publication date December 2015. 1 3 10 30 100 300 Program Volume 15 ADVANCED HEART FAILURE Left Ventricular Assist Device (LVAD) Implantation CARDIOVASCULAR SERVICES CARDIOVASCULAR
The John Ochsner Heart & Vascular Institute (JOHVI) has been providing ventricular assist device | (VAD) services for patients across the Gulf Coast region for over 20 years.
These devices help preserve the heart function of patients enhance the long-term VAD patient’s survival and quality of life.
OUTCOMES awaiting a heart transplant otherwise known as a bridge At JOHVI, our team of six advanced heart failure cardiologists to transplant or as a permanent treatment option known works closely with the patients’ primary cardiologist to share as destination therapy. New technology and identification in the management of patients with heart failure. of patients earlier in the heart failure disease process will OCHSNER
16 In 2015, 13 patients received LVADs as a bridge to transplant. An additional 30 patients received LVADs as a destination These devices support patients too sick to wait for a donor heart therapy, meaning they would not undergo a heart transplant to become available, helping their bodies grow stronger as they at a later date. LVADs can improve quality of life for these await their transplant surgeries. end-stage heart failure patients who are not candidates for a transplant.
Heart Transplant & VAD Volume Ochsner Medical Center, 2000–2015
Total Heart Transplants | VADs
100%100%
80%80%
60%60% 52
45 ADVANCED HEART FAILURE 43 40%40% 35 35 33 32 33 30 30 28 29 29 25 25 23 22 22 20 20%20% 17 18 18 17 15 10 10 8 5 5 6 3 3 0%0% 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
2016 annualized as of 8/8/16 17 ADVANCED HEART FAILURE Patient Survival After LVAD
Ochsner’s vast array of advanced heart failure cardiologists, The experienced members of our VAD team also work closely VAD coordinators, heart failure coordinators, advanced practice in training emergency medical services providers in communities providers, pharmacists, social workers and support personnel across the Gulf South and in neighborhoods where our VAD work diligently with patients, their family members and referring patients live. Our goal is to ensure local medical providers can providers in the ongoing care of patients after implantation. perform tests, discuss symptoms and consult with our specialists These “shared care” partnerships contribute greatly to the to determine if patients need additional care in a hospital setting consistent success of Ochsner VAD patients exceeding national or if modifications can be made at home to prevent a hospital standards in patient survival at the one- month, one-year and admission. At Ochsner, we have VAD coordinator and VAD two-year milestones. physician services on-call 24 hours a day, seven days per week.
*The Interagency Registry for Mechanically Assisted Circulatory Support is a registry VAD Patient Survival for patients who are receiving durable mechanical circulatory support device therapy Ochsner Medical Center, 2015 to treat advanced heart failure.
150% Ochsner | Intermacs*
120%
97% 92% 91% 89% 95% 90% 91% 82% 87% 81% 71% CARDIOVASCULAR SERVICES CARDIOVASCULAR
| 60%
30% OUTCOMES
0% OCHSNER 1 3 6 12 24 18 Months Post-VAD ADVANCED HEART FAILURE
19 ADVANCED HEART FAILURE Pulmonary Hypertension
The Ochsner Pulmonary Hypertension Program is the largest in the region, caring for more than 450 patients and evaluating more than 250 patients for treatment options annually. The program’s team of cardiologists, pulmonologists, rheumatologists, CARDIOVASCULAR SERVICES CARDIOVASCULAR
| radiologists, nurses, pharmacists and other providers work with each patient to develop an individualized treatment plan. Through this coordinated approach to care, patients will have access to
OUTCOMES care across the continuum including inpatient care, outpatient care, access to complex medical management, support groups, enhanced education and even lung transplantation if necessary. OCHSNER
20 ADVANCED HEART FAILURE
21 22 OCHSNEROUTCOMES | CARDIOVASCULAR SERVICES Electrophysiology
According to the American Heart Association, more than five million Americans have arrhythmias, with the most common being atrial fibrillation (AFib). Many are undiagnosed, and as the population ages and people live longer the incidence continues to rise. The risks for patients include increased risk for stroke and worsening heart failure and quality of life.
To meet the growing demand, Ochsner has added its sixth adult In 2015, we performed 203 radiofrequency ablation/pulmonary specialist and constructed its fourth dedicated Electrophysiology vein isolation procedures, representing a 495% increase in these Lab. Along with two pediatric specialists, the John Ochsner procedures over the last three years. Heart & Vascular Institute continues to lead the largest and most comprehensive center for management of complex arrhythmias and heart rhythm disorders in the Gulf South. Cardiac Rhythm Management
Implantable technology, such as pacemakers and implantable Leading the Way in Ablation Therapy cardioverter defribrillators (ICDs), continue to advance and & Rhythm Disorders serve as life-saving tools for managing a variety of heart rhythm disorders. Within the electrophysiology section, we have Radiofrequency ablation is a nonsurgical; catheter-based therapy a robust team of device management specialists on-site designed to eliminate small pieces of heart tissue within the heart to provide in-person, remote web-based and telephonic that create electrical dysfunction. At Ochsner, we work with management. In 2015, the electrophysiologists at Ochsner cardiologists throughout the Gulf Coast to assist their patients implanted 301 pacemakers and 278 ICDs. with complex AFib, ventricular tachycardia, supraventricular tachycardia and pulmonary vein isolation procedures. Furthermore, through the Ochsner group practice, we have developed special Integrated Group Practice Units (IGPUs), where physicians from multiple disciplines come together to organize care around certain medical conditions. Placing the patient at the center of care, these providers develop team-based models that ensure the best course of therapy and outcomes for the patient.
A prime example, within the electrophysiology department, ELECTROPHYSIOLOGY is the collaboration between electrophysiologists and structural heart specialists who manage patients with left atrial appendage disease. This disease, if not corrected, results in a high risk for stroke-producing blood clots among patients with AFib.
23 400%
Radiofrequency Ablation / Pulmonary Vein Isolation Procedures Ochsner Medical Center, 2012–2015 320%
240% 203
160% 124 95 80% 41
0% 2012 2013 2014 2015
1000%
Arrhythmia Procedures 800%Ochsner Medical Center, 2015
644 600% CARDIOVASCULAR SERVICES CARDIOVASCULAR
| 400% 301 278
200% OUTCOMES
52
0% OCHSNER Lead Extractions Pacemaker Implantable Cardioverter Defibrillator Ablation
24 ELECTROPHYSIOLOGY
25 Interventional Cardiology
The John Ochsner Heart & Vascular Institute is a regional referral center for complex, high-risk percutaneous coronary interventions (PCI).
In 2015, nearly 5,000 cardiac catheterization procedures angioplasty, including unprotected left main intervention were performed by our expert team of adult and pediatric and chronic total occlusions. We also take great pride in interventional cardiologists. Our interventional cardiologists training tomorrow’s physicians through our ACGME accredited CARDIOVASCULAR SERVICES CARDIOVASCULAR
| are experts in coronary and peripheral interventions as well program, which includes eight fellows annually training as arterial and venous diseases. The range of services offered in interventional coronary and peripheral vascular diseases. goes from the carotid arteries to the feet with procedures We also work with insurers and employer groups for ranging from diagnostic to advanced endovascular therapies. second opinions. The program offers the latest technology, including OUTCOMES brachytherapy, atherectomy, fractional flow reserve and intravascular ultrasound. Regionally, we collaborate with providers from across the Gulf South to offer high-risk OCHSNER
26 The rate of in-hospital mortality among patients who had PCI procedures at Ochsner in 2015 was lower when compared to rates at similar hospitals. Our team includes national leaders from both the American College of Cardiology (ACC) and the Society for Cardiac Angiography and Interventions (SCAI), who are dedicated to the nonsurgical treatment and prevention of heart attack, stroke and limb loss.
PCI In-Hospital Risk-Adjusted Mortality Ochsner Medical Center, 2015 Source: ACC-NCDR database
Ochsner | U.S. Hospitals 50th Percentile
1.90%
1.84%
1.8%
1.78% INTERVENTIONAL CARDIOLOGY
1.72% 1.7%
1.66%
1.60%
27 In 2015, the rates for major vascular complications, including death, emergency coronary artery bypass grafting and stroke with PCI procedures, at John Ochsner Heart & Vascular Institute were far better than the rates at comparable hospitals.
To serve these patients, our award-winning team has developed As national leaders in acute stroke prevention, we are experts innovative strategies to treat coronary heart disease, even in in carotid stenting and other cerebrovascular disease interventions. people who have been told they have no options; renal artery And we are regional leaders in valvuloplasty, TAVR and limb stenosis and renovascular hypertension; chronic mesenteric salvage using the latest vascular rescue therapies for patients ischemia and peripheral arterial disease. with severe ischemia or complex wounds.
Any Adverse Event for PCI Ochsner Medical Center, 2015 Source: ACC-NCDR database
Ochsner | National Cardiovascular Data Registry Compare Group
8.0%
6.9%
6.4%
4.8%
3.7% CARDIOVASCULAR SERVICES CARDIOVASCULAR
| 3.2%
1.6% OUTCOMES
0.0% OCHSNER
28 Use of fractional flow reserve (FFR) to validate lesions with stenosis between 40 and 70 percent is a best practice measure to determine the appropriateness for PCI. At JOHVI, we use FFR at nearly twice the rate of comparable hospitals. This is beneficial to patients because, with angiography alone, it is not always clear which narrowed area is most problematic. FFR offers a functional evaluation to confirm the PCI procedure will be effective or to guide the specialist to investigate other narrowed areas.
FFR Utilization Ochsner Medical Center, 2015 Source: ACC-NCDR database
Ochsner | National Cardiovascular Data Registry Compare Group
50% 44.8%
40%
30% INTERVENTIONAL CARDIOLOGY 24.9%
20%
10%
0%
29 At Ochsner, our expert interventionalists pay particular attention to the management of fluoroscopy agents and patient hydration during cardiac catheterization procedures to prevent acute kidney injury (AKI). At Ochsner, our patients are one-third less likely to develop AKI versus comparable hospitals.
PCI In Hospital Risk-Adjusted Acute Kidney Injury Ochsner Medical Center, 2015 Source: ACC-NCDR database
Ochsner | U.S. Hospitals 50th Percentile
8.0%
6.4% 6.3%
4.8% 4.6% CARDIOVASCULAR SERVICES CARDIOVASCULAR
| 3.2%
1.6% OUTCOMES
OCHSNER 0.0%
30 In 2015, John Ochsner Heart & Vascular Institute interventional cardiologists performed more procedures using radial access than comparable hospitals. Use of radial access has demonstrated reduced bleeding complications, lower readmission rates, fewer infections and shorter recovery times versus femoral access. The graph below shows a comparison between Ochsner 2015 data and the aggregate value for that metric across all U.S. patients in the National Cardiovascular Data Registry.
Diagnostic Catheter Radial Access Site Ochsner Medical Center, 2015 Source: ACC-NCDR database
Ochsner | National Cardiovascular Data Registry Compare Group
80%
64%
48% 40.6% INTERVENTIONAL CARDIOLOGY 34.3% 32%
16%
0%
31 Structural Heart and Valve Program
The Structural Heart and Valve Program is unrivaled in the region, and the Transcatheter Aortic Valve Replacement (TAVR) program is recognized as having the best outcomes combined with one of the shortest lengths of stay in the United States.
TAVR is a procedure for select patients We recently launched our nonsurgical ® CARDIOVASCULAR SERVICES CARDIOVASCULAR with severe symptomatic aortic stenosis mitral valve repair program with MitraClip,
| who are not candidates for traditional as well as multiple methods of left open chest surgery or are moderate atrial appendage closure. We take into and high-risk nonsurgical candidates. account the total patient, including TAVR uses a catheter to replace the heart frailty, lung function and patient wishes.
OUTCOMES valve instead of opening up the chest to We specialize in nonsurgical and remove the diseased valve. Since 2011, minimally invasive treatment. the Ochsner Structural Heart Team has performed over 450 TAVR procedures. OCHSNER
32 STRUCTURAL HEART AND VALVE PROGRAM
Ninety-five percent of our patients who have the TAVR procedure are able to return home the day following their procedure.
33 STRUCTURAL HEART AND VALVE PROGRAM
Transcatheter Aortic Valve Replacement
Since the inception of the TAVR program in 2010, Ochsner has become the regional leader in use of this specialized treatment for high-risk nonsurgical patients with aortic valve disease. Over 570 patients had this procedure at Ochsner with excellent outcomes and demonstrated quality of life improvement.
The Ochsner group practice integrated approach to patient-centered in one visit to enhance their patient experience. Services include multidisciplinary care is highly effective in its management all imaging studies, lab work and physician consultations with the of heart valve disease. Patients from across the Gulf South are necessary providers (i.e., interventional cardiology, cardiovascular seen in our outpatient Heart Valve Clinic and receive their full surgery, noninvasive cardiologist). medical evaluation, diagnostic workup and treatment plan
TAVR In-Hospital Mortality Ochsner Medical Center, 2015 In 2015, 150 TAVR procedures 2.3 were performed at Ochsner. Increased The In-Hospital Mortality Rate Mortality was 0.9 percent compared to an expected rate of 7.9 percent. U.S. hospitals performing CARDIOVASCULAR SERVICES CARDIOVASCULAR
| at the 50th percentile achieved Expected a 2.3 percent mortality rate. 1.00 0.9 Mortality Ochsner ranked among the 0.63 best in the United States for In-Hospital Mortality. OUTCOMES Decreased Mortality
0.00 Source: ACC-NCDR database OCHSNER Ochsner U.S. Hospitals 50th Percentile
34 TAVR Length of Stay Ochsner patients with TAVR Ochsner Medical Center, 2015 procedures had a hospital length of stay averaging one day. Comparative hospitals performing at the 90th percentile achieved 1.7 Increased a length of stay of 1.7 days. Length of Stay TAVR patients at Ochsner enjoyed the benefit of returning home much sooner than those in comparative hospitals. 1.0 Expected 1.00 Length of Stay
Decreased Length of Stay
Source: ACC-NCDR database Ochsner US Hospitals 90th Percentile
Discharge Disposition Home Ochsner Medical Center, 2015 Home Health
Skilled Nursing Facility STRUCTURAL HEART AND VALVE PROGRAM Expired
3% 9% 96% of our patients return home 1% following a TAVR procedure.
87%
35 STRUCTURAL HEART AND VALVE PROGRAM Adult Congenital Heart Disease Program
More than half the patients with congenital heart disease are now adults, and they require long-term cardiovascular management.
Eighty-five percent of adult congenital At the core of the program is the heart disease patients have moderate collaboration between adult and pediatric to severe defects that have been repaired cardiovascular specialists, who are experts but not corrected. Lifelong monitoring in managing congenital heart disease. before symptoms occur is essential. This team of dedicated professionals
CARDIOVASCULAR SERVICES CARDIOVASCULAR The Adult Congenital Heart Disease provided care for more than 600 outpatient
| Program is the only one in the Gulf encounters, over 700 specialized echos, South treating congenital heart disease 58 caths, and 90 admissions in 2015 patients in an adult setting. The team including supporting 14 deliveries by works hand in hand with referring mothers with congenital heart defects.
OUTCOMES physicians to provide care to patients The Ochsner ACHD Program offers with complex diseases. comprehensive care to adults with repaired or newly diagnosed congenital heart disease. OCHSNER
36 STRUCTURAL HEART AND VALVE PROGRAM
The Adult Congenital Heart Disease Program is the only one in the Gulf South treating congenital heart disease patients in an adult setting.
37 38 OCHSNEROUTCOMES | CARDIOVASCULAR SERVICES Noninvasive Cardiovascular Imaging
We offer the most broadly based, state-of-the-art cardiovascular imaging services in the Gulf South, including cardiac PET imaging and advanced echocardiography services, such as 3D transesophageal echo.
For cross-section imaging, we offer cardiac MRI services and We offer state-of-the-art Cardiac PET imaging services including computed tomography angiography. All noninvasive imaging stress myocardial perfusion with integration of absolute myocardial labs have achieved national certification through the Intersocietal flow, viability assessment and assessment of cardiac sarcoidosis. Accreditation Commission, ensuring high-quality patient care. We specialize in assessment of regional and global myocardial We often use multiple modalities to assess and diagnose complex ischemia in both straightforward and complex cases and assist problems. This is a strength that particularly benefits our adults in subsequent decisions for revascularization. We serve as the with congenital heart disease, structural heart disease and other major referral center in the Southeast for second opinions and highly complex cardiovascular diseases. These patients are often are also the site of several clinical trials. We are the only facility at a higher risk for irregular heartbeats, blood clots, congestive in the Southeast with the capabilities and experience to incorporate heart failure, heart attacks and even sudden cardiac death if they absolute myocardial flow into standard perfusion images such are not regularly monitored through multiple modalities. that subsequent decisions for revascularization can be achieved.
9500% Noninvasive Cardiovascular Imaging Ochsner Medical Center, 2015
7600% NONINVASIVE CARDIOVASCULAR IMAGING 21,164
5700% 5,338
3800%
1900% 974 381 467 0% Pet MRI Vascular Echo Spect 39 Preventive Medicine and Cardiac Wellness
Ochsner’s Cardiac Rehabilitation Program is professionally supervised to help patients recover from heart attacks, heart surgery and percutaneous coronary intervention procedures.
Patients begin rehabilitation while they are in the hospital. plans to exercise programs. Once a patient completes the Once discharged, patients are enrolled in a 12-week monitored process, they are encouraged to continue their own cardiac rehabilitation program that includes everything from diet rehabilitation and make routine appointments at our center.
Quality of Life Metrics Ochsner Medical Center, 2015 higher number indicates improvement
Pre | Post +11% 120% 114.9
103.6
96%
72% CARDIOVASCULAR SERVICES CARDIOVASCULAR
| 48% +10% 25.4 23.1 24% +17% OUTCOMES 16.9 14.4 +7% 8.1 8.6
OCHSNER 0% Physical Function Energy/Fatigue Pain Total Quality of Life 40 PREVENTIVE MEDICINE AND CARDIAC WELLNESS
41 42 OCHSNEROUTCOMES | CARDIOVASCULAR SERVICES 14.0%
Behavioral Metrics: Mean Scores Ochsner Medical Center, 2015 lower number indicates improvement 11.2%
Pre | Post 8.4% −30% 7.2
5.6% 5.1 −38% −42% 4.2 3.9 −36% 2.6 2.8 2.8% 2.3 1.8
0.0% Anxiety Depression Hostility Somatization
50%
Behavioral Metrics: Categorical Scores PREVENTIVE MEDICINE AND CARDIAC WELLNESS Ochsner Medical Center, 2015 40%
Pre | Post 30% −56% 25 −65% 23
20%
−40% 11 10 10% 8 6
0% Anxiety Depression Hostility 43 Lipid Metrics Ochsner Medical Center, 2015
Pre | Post
155% −1% 140 138
124% −8% 111 102 93% −3% 77 75 CARDIOVASCULAR SERVICES CARDIOVASCULAR
| 62% +5% 41 43
31% OUTCOMES −6% 3.5 3.3
OCHSNER 0% Total Cholesterol HDL-C LDL-C Triglycerides TC/HDL 44 12.0%
Inflammation Ochsner Medical Center, 2015 9.6%
Pre | Post 7.2% −4% 5.4 5.2 4.8%
2.4%
0.0% hs-CRP
60%
Anthropometrics PREVENTIVE MEDICINE AND CARDIAC WELLNESS Ochsner Medical Center, 2015 48%
Pre | Post 36% 0% 29.5 29.5 −3% 24% 23.1 22.4
12%
0% BMI % Body Fat 45 46 OCHSNEROUTCOMES | CARDIOVASCULAR SERVICES 40%
Exercise Metrics Ochsner Medical Center, 2015 32%
Pre | Post 24% +10% 20.2 18.4 +19% 16% 14.0 11.8
8%
0% Peak VO2 Heart Rate Recovery
Exercise Metrics: Heart Rate Recovery PREVENTIVE MEDICINE AND CARDIAC WELLNESS Ochsner Medical Center, 2015
Normal | Abnormal
42% 58% 49% 51%
Pre Post 47 Patient Experience Ochsner Clinic and the John Ochsner Heart & Vascular Institute are committed to delivering excellent clinical CARDIOVASCULAR SERVICES CARDIOVASCULAR
| outcomes while ensuring patients and their families receive the best overall experience in the process. We believe in transparency and seek feedback from our patients
OUTCOMES in efforts to improve our clinical care and patient experience opportunities. OCHSNER
48 PATIENT EXPERIENCE
49 Patient feedback based on results submitted to the CG-CAHPS database from all U.S. reporting medical practices in 2015.
CG-CAHPS Outpatient Office Visit Survey Ochsner Heart & Vascular Institute, 2015 Source: Press Ganey, a national hospital survey vendor
Ochsner | CG-CAHPS
100% 95.0 95.9 91.3 92.2 92.0 84.5 84.4 79.9 80% 78.3 73.6
60% CARDIOVASCULAR SERVICES CARDIOVASCULAR
| 40%
20% OUTCOMES
OCHSNER 0% Overall Doctor Rating Physician Communication Office Staff Quality Access to Care Care Coordination 50 Patient feedback based on a national survey results of discharged patients for 2015 from all U.S. hospitals medicare.gov/hospitalcompare
Cardiology Unit HCAPS Inpatient Survey Ochsner Heart & Vascular Institute, 2015
Ochsner | HCAPS Average
100%
86.6 88.3 87.2 83.5 80.7 80.0 81.4 80% 72.2 70.9 71.9 71.3 68.1 67.5 67.1 63.0 64.4 63.5 60% 53.5
40% PATIENT EXPERIENCE
20%
0% Overall Hospital Communication Response of Communication Hospital Pain Communication Discharge Care Rating with Nurses Hospital Staff with Doctors Environment Management about Medicines Information Transitions 51 Research
At any given time, more The John Ochsner Heart & Vascular Institute research program than 60 clinical trials are comprises a unique group of individuals dedicated to providing actively enrolling patients clinical research opportunities to our patients. across the spectrum of CARDIOVASCULAR SERVICES CARDIOVASCULAR
In general, clinical trials are used to test the At any given time, more than 60 clinical | conditions in the cardiology safety and effectiveness of drugs, devices trials are actively enrolling patients across research program. and medical procedures in the human the spectrum of conditions in the cardiology population. This ongoing collaboration research program. More than 1,500 patients between physician investigators and study are enrolled in over 100 trials.
OUTCOMES volunteers is one of the foundations of modern healthcare because clinical trials help set the standards for patient care. OCHSNER
52 RESEARCH Lifemarker VT: Clinical study to determine whether levels of certain substances/chemicals/compounds in blood can correlate Clinical Trials with dangerous heart rhythms in ICD patients OPTIMIZER III: Evaluation of the safety and efficacy of the Arrhythmia Clinical Trials OPTIMIZER® system in subjects with moderate-to-severe heart failure with ejection fraction between 25% and 45%: FIX-HF-5C : Clinical study to test the hypothesis that AdaptResponse PSR: The purpose of the Product Surveillance Registry is to market-released Cardiac Resynchronization Therapy (CRT) provide continuing evaluation and periodic reporting of safety ® devices that contain the AdaptivCRT (aCRT) algorithm have and effectiveness of Medtronic market-released products a superior outcome compared to standard CRT devices in CRT indicated patients with normal atrioventricular (AV) RESPOND CAS: Continued Access study to gather confirmatory conduction and left bundle branch block (LBBB) evidence on the safety of the SonRtip lead and performance of the automatic atrioventricular (AV) delay and interventricular (VV) Barostim: The purpose of this clinical trial is to develop valid delay optimization algorithm used in the PARADYM RF SONR scientific evidence for safety and effectiveness of Baroreflex cardiac resynchronization therapy with defibrillation (CRT-D) Activation Therapy™ with the Barostim neo system in subjects device (Model 9770) in a patient population that is reflective with heart failure, defined as New York Heart Association of current heart failure treatment practice (NYHA) functional Class III and left ventricular ejection fraction (LVEF) 35% despite being treated with the appropriate heart ≤ SDD for ICD: Study to show that same day discharge (SDD) failure guideline-directed therapy, excluding subjects eligible for ICD implantation is not inferior to next-day discharge (NDD) for or with a cardiac resynchronization therapy (CRT) device in terms of postoperative complications, and that SDD is more cost-effective than NDD CRT in PHTN: Clinical study to determine whether patients with advanced pulmonary hypertension improve thermodynamically UNTOUCHED: Study to assess the 18-month incidence and/or derive clinical benefit from acute cardiac resynchronization of all-cause shocks in subjects implanted with the EMBLEM subcutaneous implantable defibrillator (S-ICD) for primary ENHANCE CRT: Study is to analyze the effect of left ventricular prevention of sudden cardiac death (LV) lead pacing location in the non-left bundle branch block (NLBBB) heart failure (HF) patient population. The LV lead pacing Vest Registry: Randomized, single-blind, study on the prevention location will be guided by either the pacing site with the largest of sudden death after myocardial infarction using a LifeVest amount of dyssynchrony as measured by the LV electrical delay wearable cardioverter-defibrillator (QLV) or the physician’s standard of care implant approach
LEADLESS II: Prospective, nonrandomized, single-arm, international multicenter, clinical safety and effectiveness of the Nanostim leadless pacemaker system in patients who are indicated for a VVIR pacemaker RESEARCH
53 Cardiac Surgery Clinical Trials Consultative Clinical Trials
COUNTER-HF: Prospective, multicenter, randomized trial to assess ARTEMIS: A practical multicenter, cluster-randomized clinical the safety and efficacy of the C-Pulse® System (implantable, non- trial to assess the impact of copayment reduction by equalizing blood-contacting, non-obligatory heart assist device) the copayment of clopidogrel and ticagrelor
EXCLUDER: Prospective, nonrandomized, multicenter, single- INTCAR: Hypothermia Registry designed to gain a better arm evaluation to assess the safety and efficacy of the Iliac understanding of the pathophysiology, process of care, Branch Excluder Device in subjects with common iliac artery and outcomes associated with out-of-hospital cardiac arrest aneurysms (CIAAs) or aortoiliac aneurysms (AIAs)
HeartMate III: Study to evaluate the safety and effectiveness Heart Failure Clinical Trials of the HM III left ventricular assist system by demonstrating non-inferiority to the HM II LVAS (HM II) when used for the BEAT: Multicenter, double-blind, randomized, placebo- treatment of advanced, refractory, left ventricular heart failure controlled Phase 3 study to assess the efficacy and safety of BPS-314d-MR (modified-release beraprost sodium) when HW-004A: Prospective, randomized, controlled, unblinded, added-on to inhaled treprostinil (Tyvaso®) in patients with multicenter trial evaluating the stroke incidence in patients pulmonary arterial hypertension receiving a HeartWare HVaD CardioMEMS: Study of CardioMEMS HF System (Implantable HW-006: A prospective, multicenter, single-arm study PA pressure sensor) in patients with NYHA class III heart failure to evaluate the thoracotomy implant technique in up to in a commercial setting 120 subjects implanted via thoracotomy with the HeartWare HVAD® System and enrolled in the Interagency Registry for ENDEAVOUR: Study is to evaluate the safety and efficacy Mechanically Assisted Circulatory Support (INTERMACS®) of revusiran (ALN-TTRSC) in patients with transthyretin (TTR) protocol and database mediated familial amyloidotic cardiomyopathy IMPELLA PAS: Prospective, single-arm, multicenter post OAR: Registry is to observe short- and long-term clinical approval study to monitor postmarket approval safety and outcomes in heart transplant recipients who receive regular outcomes trends of the Impella RP device in patients with AlloMap testing as part of allograft rejection surveillance RV failure deemed to require hemodynamic support OPUS: Prospective, observational drug registry to characterize SynCardia 50cc TAH for BTT: Study to evaluate whether the
CARDIOVASCULAR SERVICES CARDIOVASCULAR the safety profile (including primarily potential serious hepatic
| 50cc TAH-t can safely support and provide probable benefit risks) and to describe clinical characteristics and outcomes to transplant-eligible pediatric patients (aged 10–18 years) of patients newly treated with Opsumit (macitentan) in the and can safely and effectively support transplant-eligible adult postmarket setting patients (aged 19–75 years) at imminent risk of death from biventricular failure without experiencing permanent disabling, OUTCOMES stroke-related deficits OCHSNER
54 PARACHUTE IV: Percutaneous ventricular restoration using the Interventional Clinical Trials Parachute implant (Structural heart medical device) in patients with ischemic heart failure and dilated left ventricles ABSORB IV: A prospective, randomized, single-blind, multicenter study to evaluate the Absorb™ BVS, the Everolimus Eluting REPORT HF: The proposed observational study is a multinational Bioresorbable Vascular Scaffold, in the treatment of subjects HF-disease registry that will document the routine patterns of with de novo native coronary artery lesions diagnosis and medical care for heart failure as well as treatment type, long-term HF-related clinical events, and re-admission rates AVERT: Randomized, single-blind trial of the AVERT System following the acute admission index event to reduce contrast media (CM) exposure to the kidneys during percutaneous coronary procedures thereby reducing the risk Secret of CHF: Phase 3 Randomized, Double-Blind, Placebo of contrast induced nephropathy (CIN) Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With BEST CLI: Randomized study to compare the effectiveness Challenging Volume Management of best available surgical treatment with best available endovascular treatment in adults with critical limb ischemia SOPRANO: Trial to evaluate the effect of macitentan (CLI) who are eligible for both treatment options 10 mg on PVR as compared to placebo in subjects with PH after LVAD implantation CALM: Trial to evaluate the safety and performance of the MobiusHD system in subjects with resistant hypertension Tafamidis: A Multicenter, International, Phase 3, Double-blind, Placebo-controlled, Randomized Study To Evaluate The Efficacy, COAPT: Cardiovascular outcomes assessment of the MitraClip Safety, And Tolerability Of Daily Oral Dosing Of Tafamidis percutaneous therapy for heart failure patients with functional Meglumine 20 Mg Or 80 Mg In Comparison To Placebo In mitral regurgitation (COAPT) trial to confirm the safety and Subjects Diagnosed With Transthyretin Cardiomyopathy effectiveness of the MitraClip System for the treatment of moderate-to-severe or severe functional mitral regurgitation THAOS Registry: Global, multi-center, longitudinal observational (FMR) in symptomatic heart failure subjects who are treated per survey open to all patients with transthyretin-associated standard of care and who have been determined by the site’s amyloidosis (ATTR), including ATTR-PN (polyneuropathy), ATTR-CM local heart team as not appropriate for mitral valve surgery (cardiomyopathy) and wild-type ATTR-CM CREST 2: Two parallel multicenter randomized, observer- USPella Registry: Multicenter registry of Impella 2.5 patients blinded endpoint clinical trials. One trial will assess treatment evaluating the safety and feasibility of left ventricular support with differences between intensive medical management alone the Impella 2.5 during high-risk percutaneous coronary intervention compared to carotid endarterectomy (CEA) plus intensive (PCI) and treatment of acute myocardial infarction (AMI) medical management. The parallel trial will assess treatment differences between intensive medical management alone compared to carotid artery stenting (CAS) plus intensive medical management RESEARCH
55 FMD Registry: Data registry to determine the natural Vascular Clinical Trials course of fibromuscular dysplasia and to determine which procedures are more effective to relieve symptoms and VOYAGER PAD: Study to test whether rivaroxaban added reduce adverse outcomes to standard of care treatment, when compared to placebo, has the potential to reduce the incidence of clinical events LMISR: Study to determine if less-invasive CT scan can provide related to the clots and complications of the heart and brain the same information as an angiogram to assess for re-stenosis (CV death, MI, or stroke) or the legs (acute limb ischemia in the left main stent or major amputation) in patients who had undergone recent procedure(s) to improve the blood flow of their legs PARACHUTE: Randomized, multicenter trial designed to evaluate the PARACHUTE implant in the treatment of ischemic heart failure Humanitarian Use Devices PARTNER 2: Randomized trial to determine the safety and effectiveness of the Edwards SAPIEN XT and the Edwards ENTERPRISE: The ENTERPRISE vascular reconstruction SAPIEN 3 transcatheter heart valve and delivery systems that device and delivery system is indicated for the treatment are intended for use in patients with symptomatic, calcific, of wide-neck, intracranial, saccular or fusiform aneurysms severe aortic stenosis arising from a parent vessel with a diameter of ≥ 3 mm and ≤ 4 mm. Wide-neck is defined as having a neck width SCAFFOLD: Multicenter, single-arm, prospective study ≥ 4mm or a dome-to-neck ratio <2 comparing the GORE® Carotid Stent to a performance goal developed from carotid endarterectomy (CEA) outcomes JOSTENT: The JOSTENT Graft Master is indicated for use in the treatment of free perforations, defined as free contrast extravasation into the pericardium, in native coronary vessels Pediatric Interventional Clinical Trials or saphenous vein bypass grafts >2.75 mm in diameter WINGSPAN: The Wingspan Stent System (“Wingspan”) ASO: Prospective, multicenter, case-cohort study to identify is indicated for improving cerebral artery lumen diameter potential risk factors associated with the occurrence of erosion in patients with intracranial atherosclerotic disease, refractory due to implantation of the AMPLATZER™ septal occluder (ASO) to medical therapy, in intracranial vessels with greater than or equal to 50% stenosis that are accessible to the system PARCS: Study of the covered Cheatham-Platinum stent (CCPS) for repair of tears that occur in the pulmonary artery during Impella RP: The Impella RP system is indicated for providing dilation (enlargement) of a conduit (passageway) connecting CARDIOVASCULAR SERVICES CARDIOVASCULAR
circulatory assistance for up to 14 days in pediatric or adult | the right ventricle of the heart to the pulmonary arteries patients with a body surface area ≥1.5 m2 who develop acute right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant or open-heart surgery OUTCOMES OCHSNER
56 RESEARCH Arena R, Guazzi M, Lianov L, Whitsel L, Berra K, Lavie CJ, Kaminsky L, Williams M, Hivery MF, Cherie Franklin N, Myers J, Dengel D, Lloyd-Jones DM, Pinto FJ, Cosentino F, Halle M, Publications Gielen S, Dendale P, Niebauer J, Pelliccia A, Giannuzzi P, Corra U, Piepoli MF, Guthrie G, Shurney D, AHA Writing Group, Arena Agarwal SK, Nadkarni GN, Yocoub R, Patel AP, Jenkins JS, R, Berra K, Dengel D, Franklin NC, Guvert MF, Kaminsky L, Lavie Collins TJ, Annapureddy N, Kumbala D, Bodana S, Benjo AM. CJ, Lloyd-Jones DM, Myers J, Whitsel L, Williams M, ESC/EACPR Comparison of cutting balloon angioplasty and percutaneous Writing Group, Corra U, Cosentino F, Dendale P, Giannuzzi P, balloon angioplasty of arteriovenous fistula stenosis: A meta- Gielen S, Guazzi M, Halle M, Niebauer J, Pelliccia A, Piepoli MF, analysis and systematic Review of randomized clinical trials. Pinto FJ, ACPM Writing Group, Guthrie G, Lianov L, Shurney J Interv Cardiol. 2015 Jun; 28(3): 288–95. D. Healthy lifestyle interventions to combat noncommunicable disease – a novel nonhierarchical connectivity model for key Alpert MA, Lavie CJ, Agrawal H, Kumar SA. Cardiac effects of stakeholders: a policy statement from the American Heart obesity: pathophysiologic, clinical and prognostic. J Cardiopulm Association, European Society of Cardiology, European Association Rehabil Prev 2016 Jan–Feb; 36(1): 1–11 for Cardiovascular Prevention and Rehabilitation, and American College of Preventive Medicine. Eur Heart J 2015 Aug 14; 36(31): Archer E, Lavie CJ. Evidence for sugary beverages and diabetes 2097–2109. link is not so sweet, compelling or even plausible. BMJ 2015; [Published 21 July 2015]. Arena R, Lavie CJ, Borghi-Silva A, Daugherty J, Bond S, Phillips SA, Guazzi M. Exercise training in group 2 pulmonary Archer E, Pavela G, Lavie CJ. A discussion of the refutation hypertension: which intensity and what modality. Prog of memory-based dietary assessment methods (M-BMs): Cardiovasc Dis 2015 Nov 10 [Epub ahead of print]. the rhetorical defense of pseudoscientific and inadmissible evidence. Mayo Clin Proc 2015 Dec; 90(12): 1736–9. Arena R, Lavie CJ, Cahalin LP, Briggs PD, Guizilini S, Daugherty J, Chan WM, Borghi-Silva A. Transforming cardiac rehabilitation Archer E, Pavela G, Lavie CJ. The inadmissibility of what we eat into broad-based healthy lifestyle programs to combat in America and NHANES dietary data in nutrition and obesity noncommunicable disease. Expert Rev Cardiovasc Ther 2016 research and the scientific formulation of National Dietary Jan; 14(1): 23–25 [Epub 2015 Oct 29]. Guidelines. Mayo Clin Proc 2015 Jul; 90(7): 911–26. Arena R, Lavie CJ, Hivert MF, Williams MA, Briggs PD, Guazzi M. Arena R et al. Healthy lifestyle interventions to combat Who will deliver comprehensive healthy lifestyle interventions noncommunicable disease – a novel nonhierarchical to combat non-communicable disease? Introducing the healthy connectivity model for key stakeholders: a policy statement lifestyle practitioner discipline. Expert Rev Cardiovasc Ther 2016 from the American Heart Association, European Society of Jan; 14(1): 15–22 [Epub 2015 Nov 2] Cardiology, European Association for Cardiovascular Prevention and Rehabilitation, and American College of Preventive Arena R, Lavie CJ. In response to: lifestyle medicine in Expert Medicine. Eur Heart J 2015 Aug 14; 36(31): 2097–2109. Review of Cardiovascular Therapy. Expert Rev Cardiovasc Ther
2015 Dec 18 [Epub ahead of print] RESEARCH
57 Arena R, Lavie CJ. The healthy lifestyle team is central to Campbell P, Krim SR, Ventura HO. The Bi-Directional Impact the success of accountable care organizations. Mayo Clin Pro Of Two Chronic Illnesses: Heart Failure And Diabetes – A Review 2015 May; 90(5): 572–6. Of The Epidemiology And Outcomes. Cardiac Failure Review. 2015; 1(1): 8–10 Babu AS, Raman VG, Arena R, Lavie CJ. Time to focus on preventing coronary artery diseases through exercise training Campbell P, Ventura HO. Impact of ethnicity and race on in normoglycemic individuals. Mayo Clin Proc 2015 Mar; response to angiotensin-converting enzyme inhibitors in heart 90(3): 418. failure. J Card Fail 2015 Jun; 21(6): 457–9
Becofsky KM, Shook RP, Sui X, Wilcox S, Lavie CJ, Blair SN. Cardoso RN, Benjo AM, Collins T, Garcia D, Macedo FY, El- Influence of the source of social support and size of social Hayek G, Zamora C, Aziz E, Jenkins JS. Vascular Brachytherapy network on all-cause mortality. Mayo Clin Proc 2015 Jul; versus Drug-Eluting Stents in the Treatment of In-stent 90(7): 895–902. Restenosis: a Meta-Analysis of Long Term Outcomes. Catheter Cardiovasc Interv. 2016 Feb 1; 87(2): 200–8. Bober RM, Jahangir E. What is ischemia and how should this be defined based on modern imaging? Prog Cardiovasc Chittal P, Babu AS, Lavie CJ. Obesity paradox: does fat alter Dis 2015; 57: 537–554. outcomes in chronic obstructive pulmonary disease? COPD 2015 Feb; 12(1): 14–8. Bober RM, Morin DP. Utilizing PET-Stress to Assess the Effect of Coronary Revascularization on Myocardial Blood Flow. Cilingiroglu M, Patel RAG, Dean LS. Late breaking trials of Expert Rev Cardiovasc Ther. (Invited, submitted, under review) 2014 in structural heart disease and peripheral arterial disease: Commentary covering ACC, EuroPCR, SCAI, TCT, VIVA, ESC, Bober RM, Thompson C, Morin DP. The Effect of Coronary and AHA. Catheter Cardiovasc Interv. 2015 Jul; 86(1): 80–4. Revascularization on Myocardial Blood Flow as Assessed by Stress Positron Emission Tomography. (Accepted, in press) Clennin MN, Payne JP, Rienzi EG, Lavie CJ, Blair SN, Pate RR, Sui X. Association between cardiorespiratory fitness and health- Brooks GC, Lee BK, Rao R, Lin F, Morin DP, Zweibel SL, related quality of life among patients at risk for cardiovascular Buxton AE, Pletcher MJ, Vittinghoff E, Olgin JE on behalf disease in Uruguay. PloS One 2015 Apr 22; 10(4): e0123989. of the PREDICTS investigators. Predicting persistent left ventricular dysfunction following myocardial infarction: Creager MA, Gornik HL, Gray BH, Hamburg NM, Iobst WF, From the PREDiction of ICd Treatment Study (PREDICTS). Mohler ER 3rd, White CJ. COCATS 4 Task Force 9: Training J Am Coll Cardiol. (Accepted, in press.) in Vascular Medicine: Endorsed by the Society for Vascular Medicine. Vasc Med. 2015 Aug; 20(4): 384–94.
CARDIOVASCULAR SERVICES CARDIOVASCULAR Cahalin LP, Kaminsky L, Lavie CJ, Briggs P, Cahalin BL, Myers J,
| Forman DE, Patel MJ, Pinkstaff SO, Arena R. Development and Creager MA, Gornik HL, Gray BH, Hamburg NM, Iobst WF, implementation of worksite health and wellness programs: Mohler ER 3rd, White CJ. COCATS 4 Task Force 9: Training a focus on non-communicable disease. Prog Cardiovasc Dis in Vascular Medicine. J Am Coll Cardiol. DOI:10.1016/j. 2015 Jul–Aug; 58(1): 94–101. jacc.2015.03.025 OUTCOMES OCHSNER
58 Dasari TW, Saucedo JF, Krim SR, Mohamad Alkhouli M, Fonarow Franklin BA, Lavie CJ. Impact of statins on physical activity GC, Alvarez R, MD, Ibrahim H, Dai D, Wang TY, Costa M, Lindenfeld and fitness: ally or adversary? Mayo Clin Proc 2015 Oct; J, Messenger JC. Clinical Characteristics and in-hospital Outcomes of 90(10): 1314–9. Heart Transplant Recipients with Allograft Vasculopathy Undergoing Percutaneous Coronary Intervention: Insights from The National Franklin NC, Lavie CJ, Arena. Personal health technology: Cardiovascular Data Registry. Am Heart J. 2015; 170: 1086–1091 a new era in cardiovascular disease prevention. Postgrad Med 2015 Mar; `17(2): 150–8. Deichmann RE, Lavie CJ, Asher T, DiNicolantonio JJ, O’Keefe JH, Thompson PD. The interaction between statins and exercise: Gander JC, Sui X, Hebert JR, Hazlett LJ, Cal B, Lavie CJ, Blair mechanisms and strategies to counter the musculoskeletal SN. Association of cardiorespiratory fitness with coronary side effects of this combination therapy. The Ochsner Journal heart disease in asymptomatic men. Mayo Clin Proc 2015 Oct; 2015;15:429-437. 90(10):1372-9.
DiNicolantonio JJ, Bhutani J, Lavie CJ, O’Keefe JH. Evidence- Giri J, Parikh SA, Kennedy KF, Weinberg I, Donaldson C, Hawkins based diuretics: focus on chlorthalidone and indapamide. BM, McCormick DJ, Jackson B, Armstrong EH, Ramchand P, White Future Cardiol 2015 Mar; 11(2): 203–17. CJ, Jaff MR, Rosenfield K, Yeh RW. Proximal versus distal embolic protection for carotid artery stenting. A National Cardiovascular Data DiNicolantonio JJ, Chatterjee S, Lavie CJ, Bangalore S, O’Keefe Registry Analysis. JACC Cardiovasc Interv. 2015; 8(4): 609–15. JH. Ezetimibe plus moderate-dose simvastatin after acute coronary syndrome: what are we IMPROVEing on? Am J Med Guazzi M, Phillips SA, Arena R, Lavie CJ. Endothelial dysfunction 2015 Aug 128(8): 914.e1–4. and lung capillary injury in cardiovascular diseases. Prog Cardiovasc Dis 2015 Mar–Apr; 57(5): 454–62. DiNicolantonio JJ, Fares H, Niazi AK, Chatterjee S, D’Ascenzo F, Cerrato E, Bondi-Zoccai G, Lavie CJ, Bell DS, O’Keefe JH. Hawkins BM, Kennedy KF, Aronow HD, Nguyen LL, White B-Blockers in hypertension, diabetes, heart failure and acute CJ, Rosenfield K, Normand SL, Spertus JA, Yeh RW. Hospital myocardial infarction: a review of the literature. Open Heart variation in carotid stenting outcomes. JACC Cardiovasc Interv. 2015 Mar 21; 2(1): e000230. 2015 May; 8(6): 858–63.
Drenowatz C, Sui X, Fritz S, Lavie CJ, Beattie PF, Church TS, Jaff MR, Rosenfield K, Scheinert D, Rocha-Singh K, Benenati Blair SN. The association between resistance exercise and J, Nehler M, White CJ. Drug-coated balloons to improve cardiovascular disease risk in women. J Sci Med Sport 2015 femoropopliteal artery patency: Rationale and design of the Nov; 18(6): 632–6 LEVANT 2 trial. Am Heart J. 2015 169(4): 479–485.
Ernstsen L, Rangul V, Nauman J, Nes BM, Dalen H, Krokstad Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, S, Lavie CJ, Blair SN, Wisloff U. Am J Med 2016 Jan; 129(1): Reekers J, Norgren L. An update on methods for revascularization 82–88 e1 [Epub 2015 Aug 21] and expansion of the TASC lesion classification to include below- the-knee arteries: A supplement to the inter-society consensus Falck RS, Shook RP, Hand GA, Lavie CJ, Blair SN. Extremes for the management of peripheral arterial disease (TASC II):
of weight gain and weight loss with detailed assessments The TASC steering committee. Catheter Cardiovasc Interv. RESEARCH of energy balance: illustrative case studies and clinical 2015 Oct; 86(4): 611–25. recommendations. Postgrad Med 2015 Apr; 127(3): 282–8.
59 Jahangir E, Lipworth L, Edwards T, Kabagambe E, Mumma Krim SR, Vivo RP, Campbell P, Estep JD, Fonarow GC, Naftel DC, M, Mensah G, Fazio S, Blot W, Sampson U. Smoking, sex, risk Ventura HO. Regional differences in use and outcomes of left factors, and abdominal aortic aneurysms: A prospective study ventricular assist devices: Insights from the Interagency Registry of 18.782 persons over age 65 in the Southern Community for Mechanically Assisted Circulatory Support Registry. Cohort Study. Journal of Epidemiology and Community Health. 2015 May; 69(5): 481–8. PMID: 25563744. Krishnamoorthy P, Gang J, Sharma A, Palaniswamy C, Shah N, Lanier G, Patel NC, Lavie CJ, Ahmad H. Gender differences and Jahangir E, Polin NM, Lavie CJ, Fazio S. The link between lipids, predictors of mortality in Takotsubo Cardiomyopathy: analysis statins and cancer: is there a role for cardio-oncology? Future from the National Inpatient Sample 2009-2010 Database. Cardiol 2015 Jul; 11(4): 389–93. Cardiology 2015 Jul 7; 132(2): 131–136 [Epub ahead of print].
Jahangir E, Shah S, Shum K, Baxter C, Fitzpatrick JD, Cole Lavie CJ, Alpert MA, Ventura HO. Risks and benefits of weight J, Gilliland Y, Polin NM. Risk assessment and management loss in heart failure. Heart Fail Clin 2015 Jan; 11(1): 125–31. of Anthracycline and HER2 receptor inhibitor-induced cardiomyopathy. South Med J 2015; 108: 71–78. Lavie CJ, Archer E, Shook RP, Blair SN. Metabolically healthy obesity, fitness, and prognosis (letter). Ochsner J 2015 Summer; Jalbert JJ, Nguyen LL, Gerhard-Herman MD, Jaff MR, White CJ, 15(2): 122–123. Rothman AT, Seeger JD, Kumamaru H, Williams LA, Chen CY, Liu J, Tsai TT, Aronow HD, Johnston JA, Brott TJ, Setoguchi S. Lavie CJ, Arena R, Swift DL, Johannsen NM, Sui X, Lee DC, Outcomes after carotid artery stenting in medicare beneficiaries, Earnest CP, Church TS, O’Keefe JH, Milani RV, Blair SN. 2015 to 2009. JAMA Neurol. 2015: 72(3): 276–86. Exercise and the cardiovascular system: clinical science and cardiovascular outcomes. Circ Res 2015 Jul 3; 117(2): 207–19. Keswani AN, Williams C, Fuloria J, Polin NM, Jahangir E. Rituximab induced acute ST elevation myocardial infarction. Lavie CJ, Blair SN. A prescription to move: giving exercise its The Ochsner Journal. 2015; 15: 187–190. PMID: 26130984. due. The Heart.org Medscape 2015 Jan 8.
King SB 3rd, Babb JD, Bates ER, Crwford MH, Dangas GD, Lavie CJ, De Schutter A, Milani RV. Body composition and the Voeltz MD, White CJ. COCATS 4 Task Force 10: Training obesity paradox in coronary heart disease: can heavier really be in Cardiac Catheterization.” J Am Coll Cardiol. 2015. DOI: healthier? Heart 2015 Oct; 101(20): 1610–1. 10.1016/j.jacc.2015.03.026 Lavie CJ, De Schutter A, Milani RV. Healthy obese versus Krim SR, Cambell PT, Desai S, Mandras S, et al. Clinical Profiles unhealthy lean: the obesity paradox. Nat Rev Endocrinol 2015 and Outcomes of Cardiac transplant recipients Using Allomap Jan; 11(1): 55–62,
CARDIOVASCULAR SERVICES CARDIOVASCULAR and Cylex Immuknow Assays. The Journal of Heart and Lung
| Transplantation. April 2015; 34 (4): S295. Lavie CJ, DiNicolantonio JJ, O’Keefe JH, Milani RV. Do statins cause or prevent dementia? Eur J Neurol 2015 Jun; 22(6): 885–6. Krim SR, Campbell PT, Desai S, Mandras S, Patel H, Eiswirth C, Ventura HO. Management of Patients Admitted with Acute Lavie CJ, Kramer CM. Fitness, fatness, and the obesity paradox.
OUTCOMES Decompensated Heart Failure. Ochsner J. 2015; 15(3): 284–9 ACCEL Audio J 2015; 47(9): Disc 3, #7. OCHSNER
60 Lavie CJ, Kramer CM. Leisure-time running reduces risk of Lee DC, Pate RR, Lavie CJ, Sui X, Church TS, Blair SN. all-cause and cardiovascular mortality. ACCEL Audio J 2015; Reply: “add 10 min for your health”: the new Japanese 47(9); Disc 3, #6. recommendation for physical activity based on dose-response analysis. J Am Coll Cardiol 2015 Mar 24: 65(11): 1154–5. Lavie CJ, Lee DC, Blair SN. Preventing diabetes via fitness. ACC.Org 2015; [Published online Oct 21]. Lewis GF, Harless AC, Vazquez L, Abi Samra FM, Bernard ML, Khatib S, Polin GM, Morin DP. Natural History and ICD Lavie CJ, Lee DC, Sui X, Arena R, O’Keefe JH, Church TS, Implantation Following Revascularization for Stable Coronary Milani RV, Blair SN. Effects of running on chronic diseases and Artery Disease with Depressed Ejection Fraction. Clin Cardiol cardiovascular and all-cause mortality. Mayo Clin Proc 2015 2015 Dec; 38(12): 715–9. Nov; 90(11): 1541–52 [Epub 2015 Sep 8] Li H, Sui X, Huang S, Lavie CJ, Wang Z, Blair SN. Secular change Lavie CJ, O’Keefe JH, Sallis RE. Exercise and the heart – in cardiorespiratory fitness and body composition of women: the harm of too little and too much. Curr Sports Med Rep the Aerobics Center Longitudinal Study. Mayo Clin Proc 2015 2015 Mar–Apr; 14(2): 104–9. Jan; 90(1): 43–52.
Lavie CJ, Sharma A, Alpert MA, De Schutter A, Lopez-Jimenez F, Mandras SA, Oleck S, Ventura H. Pulmonary Arterial Hypertension Milani RV, Ventura HO. Update on obesity and obesity paradox and the Failing Ventricle: Getting It Right. Cardiovascular Innovations in heart failure. Prog Cardiovasc Dis 2015; [Epub ahead of print]. and Applications. 2015; 1 (1): 81–91.
Lavie CJ, Ventura HO, Milani RV, Arena R. Critical impact Menezes AR, Lavie CJ, De Schutter A, Milani RV, O’Keefe of fitness in the prevention and treatment of heart failure. J, DiNicolantonio JJ, Morin DP, Abi Samra FA. Lifestyle Am Heart J 2015 Feb; 169(2): 194–6. Modification in the Prevention and Treatment of Atrial Fibrillation. Prog Cardiovasc Dis 2015; 117–125. Lavie CJ, Ventura HO. The obesity paradox in heart failure: is it all about fitness, fat or sex? JACC Heart Fail 2015 Nov; 3(11): Milani RV, Lavie CJ. Health care 2020: reengineering health 927–30 [Epub 2015 Oct 7] care delivery to combat chronic disease. Am J Med 2015 Apr; 128(4): 337–43. Lavie CJ. Special Editor’s Page – Two Years as Editor-in-Chief. Prog Cardiovasc Dis 2015;[Epub ahead of print]. Morin DP, Estes NAM III. Advances in the Prevention and Treatment of Atrial Fibrillation. Prog Cardiovasc Dis 2015; 103–4. Lavie CJ. Straight Talk: New cardiac medications: great opportunities and tough challenges. Cardiosource Plus Morin DP. Laser-Assisted Extraction of a Pacing Lead with 2015 Aug. a Supraclavicular Course. Heart Rhythm Case Reports 2015; 1(3): 120–122. Lavie CJ. Straight Talk: The new prevention guidelines a year later. Cardiosource World News 2015 Mar. Morris PB, Ference BA, Jahangir E, Feldman DN, Ryan JJ, Bahrami H, El-Chami MF, Bhakta S, Winchester DE, Al-Mallah
Lee DC, Lavie CJ, Vedanthan R. Optimal dose of running MH, Shields MS, Deedwania P, Mehta LS, Phan BAP, Benowitz RESEARCH for longevity: is more better or worse? J Am Coll Cardiol NL. Cardiovascular effects of cigarette smoke exposure 2015 Feb 10; 65(5): 420–2. and electronic cigarettes. Journal of American College of Cardiology. 2015 Sept; 66(12): 1378–91. PMID: 26383726.
61 Myers J, McAuley P, Lavie CJ, Despres JP, Arena R, Kokkinos P. Pandey A, Berry JD, Lavie CJ. Cardiometabolic disease leading Physical activity and cardiorespiratory fitness as major markers to heart failure: better fat and fit than lean and lazy. Curr Heart of cardiovascular risk: their independent and interwoven Fail Rep 2015 Oct; 12(5): 302–8. importance to health status. Prog Cardiovasc Dis 2015 Jan–Feb; 57(4): 306–14. Park YM, Sui X, Liu J, Zhou H, Kokkinos PF, Lavie CJ, Hardin JW, Blair SN. The effect of cardiorespiratory fitness on age-related Nadkarni GN, Konstantinidis I, Patel A, Yacoub R, Kumbala D, lipids and lipoproteins. J Am Coll Cardiol 2015 May 19: 65(19): Patel RAG, Annapureddy N, Pakanati KC, Simoes PK, Javed F, 2091–100. Benjo AM. Trimetazidine Decreases Risk of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease: A Parto P, Lavie CJ, Arena R, Ventura HO. Preventing heart failure Meta-Analysis of Randomized Controlled Trials. J Cardiovasc with exercise training. Curr Cardiovasc Risk Rep 2015; 9: 44 Pharmacol Ther. 2015 Nov; 20(6): 539–46. [Published online Aug 26].
Nanjundappa RPA, Patel RAG, Bansal A, Patel H, Masvidal D, Parto P, Lavie CJ, Swift D, Sui X. The role of cardiorespiratory Cambell P, Desai S, Mandras S, Collins T, White CJ, Ventura fitness on plasma lipid levels. Expert Rev Cardiovasc Ther 2015 H. Outcomes after prophylactic Intra-aortic Balloon Pump Nov; 13(11): 1177–83 [Epub 2015 Oct 5] Insertion Prior to Elective Surgical Left Ventricular Assist Device Implantation. Journal of the American College of Cardiology. Patel DA, Lavie CJ, Gilliland YE, Shah SB, Dinshaw HK, Milani March 2015; 65 (10S): A889. RV. Prediction of all-cause mortality by the left atrial volume index in patients with normal left ventricular filling pressure O’Keefe EL, diNicolantonio JJ, Patil H, Hetzberg JH, Lavie CJ. and preserved ejection fraction. Mayo Clin Proc 2015; Lifestyle choices fuel epidemics of diabetes and cardiovascular 90: 1499–1505. disease among Asian Indians. Prog Cardiovasc Dis 2015 Aug 13 [Epub ahead of print]. Patel MR, Conte MS, Cutlip DE, Dib N, Geraghty P, Gray W, Hiatt WR, Ho M, Ikeda K, Ikeno F, Jaff MR, Jones WS, Kawahara O’Keefe JH, Lavie CJ, Guazzi M. Part 1: potential dangers of M, Lookstein RA, Mehran R, Misra S, Norgren L, Olin JW, Povsic extreme endurance exercise: how much is too much? Part 2: TJ, Rosenfield K, Rundback J, Shamoun F, Tcheng J, Tsai TT, screening of school-age athletes. Prog Cardiovasc Dis 2015 Suzuki Y, Vranckx P, Wiechmann BN, White CJ, Yokoi H, Krucoff Jan–Feb; 57(4): 396–405. MW. Evaluation and treatment of patients with lower extremity peripheral artery disease: Consensus definitions from peripheral Ortega FB, Cadenas-Sanchez C, Sui X, Blair SN, Lavie CJ. Role academic research consortium (PARC). J Am Coll Cardiol. of fitness in the metabolically healthy but obese phenotype: 2015 65(9): 931–941. a review and update. Prog Cardiovasc Dis 2015 Jul–Aug;
CARDIOVASCULAR SERVICES CARDIOVASCULAR 58(1): 76–86. Prasad VK, Drenowatz C, Hand GA, Lavie CJ, Sui X, Demello
| M, Blair SN. Association between cardiorespiratory fitness and Owens AP, Edwards TL, Antoniak S, Geddings JE, Jahangir E, submaximal systolic blood pressure among young adult men: Wei W, Denny JC, Boulaftalia Y, Wolfgang B, Daugherty A, a reversed J-curve pattern relationship. J Hypertens 2015 Nov; Sampson UK, Mackman N. Platelet inhibitors reduce rupture 33(11): 2239–44.
OUTCOMES in a mouse model of established abdominal aortic aneurysm. Atherosclerosis, Thrombosis, and Vascular Biology. 2015 Jul 2. Prasad VK, Drenowatz C, Hand GA, Lavie CJ, Sui X, Demello M, PMID: 26139462. Blair SN. Relation of body’s lean mass, fat mass and body mass index with submaximal systolic blood pressure among young OCHSNER adult men. Am J Cardiol 2015; [Epub ahead of print]. 62 Prasad VK, Drenowatz C, Hand GA, Lavie CJ, Sui X. Demello M, Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado Blair SN. Cardiorespiratory fitness, body fatness and submaximal C, Metzger DC, Brodmann M, Pilger E, Zeller T, Krishnan P, systolic blood pressure among young adult women. J Womens Gammon R, Müller-Hülsbeck S, Nehler MR, Benenati JF, Scheinert Health (Larchmt) 2015 Dec 1; [Epub ahead of print]. D; LEVANT 2 Investigators. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. N Engl J Med. 2015 Jul 9; Priester T, Alasnag M, Barker C, Freeman A. Growth outside of 373(2): 145–53. one’s comfort zone: The importance of global health experiences in the formulation of new cardiologists. Journal of American Rosenthal TM, Morin DP. A little Red Bull may give you wings, College of Cardiology. doi: 10.1016/j.jacc.2015.10.089. but it probably will not affect your [Epub ahead of print] Rosenthal TM, Stahls PF III, Abi Samra FM, Bernard ML, Khatib Qian F, Fonarow GC, Krim SR, Vivo RP, Cox M, Hannan EL, S, Polin GM, Xue JQ, Morin DP. The T-peak to T-end Interval Shaw BA, Hernandez AF, Eapen ZJ, Yancy CW, Bhatt DL. for Long-term Prediction of Ventricular Tachyarrhythmia and Characteristics, quality of care, and in-hospital outcomes Mortality Among Primary-Prevention ICD Patients. Heart of Asian-American heart failure patients: Findings from the Rhythm 2015; 12(8): 1789–1797. American Heart Association Get With The Guidelines-Heart Failure Program. Int J Cardiol. 2015; 189: 141–7 Ross R, Blair S, de Lannoy L, Despres JP, Lavie CJ. Changing the endpoints for determining effective obesity management. Rab T, Kern KB, Tamis-Holland JE, Henry TD, McDaniel M, Prog Cardiovasc Dis 2015 Jan–Feb; 57(4): 330–6. Dickert NW, Cigarroa JE, Keadey M, Ramee S, Interventional Council, American College of Cardiology. Cardiac Arrest: Sardar P, Chatterjee S, Giri J, Kundu A, Tandar A, Sen P, Nairooz A treatment algorithm for emergent invasive cardiac procedures R, Huston J, Ryan JJ, Bashir R, Parikh SA, White CJ, Meyers PM, in the resuscitated comatose patient. J Am Coll Cardiol. Mukherjee D, Majersik JJ, Gray WA. Endovascular therapy for 2015; 66(1): 62–73. acute ischaemic stroke: a systematic review and meta-analysis of randomized trials. Eur Heart J. 2015 Sep 14; 36(35): 2373–80. Ricketts TA, Sui X, Lavie CJ, Blair SN, Ross R. Addition of cardiorespiratory fitness within an obesity risk classification Sardar P, Chatterjee S, Lavie CJ, Giri JS, Ghosh J, Mukherjee D, model identifies men at increased risk of all-cause mortality. Lip GY. Risk of major bleeding in different indications for new Am J Med 2015 Nov 28 [Epub ahead of print] oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials. Int J. Cardiol 2015 Jan 20; Rogers P, Hoffman R, Khatib S, Bernard M, Polin G, Abi-Samra FM, 179: 279–87. Morin DP, Collins T, Ramee S: Incidence of Pacemaker Implantation and Paravalvular Aortic Insufficiency After Transcatheter Aortic Senechal M, Johannsen NM, Swift DL, Earnest CP, Lavie CJ, Valve Replacement: A Comparison of Three Generations of Blair SN, Church TS. Association between changes in muscle Edwards SAPIEN Valves. Abstract presented at ACC 2015, quality with exercise training and changes in cardiorespiratory San Diego, California, March 2015. fitness measures in individuals with typ3 2 diabetes mellitus: results from the HART-D Study. PloS One 2015 Aug 7; 19(8): Rogers PA, Morin DP. MADIT-CRT and his many sons. Trends e0135057.
Cardiovasc Dis. (Invited, Accepted, Online before print, in press). RESEARCH Shah S, Gupti T, Ahmad R – Managing Heart Failure in Transposition of the Great Arteries. Ochsner Journal Fall 2015; 15(3): 290–296
63 Sharma A, Goel S, Lavie CJ, Arbab-Zadeh A, Mukherjee D, TASC Steering Committee, Jaff MR, White CJ, Hiatt WR, Fowkes Lazar JJ. Antithrombotic therapy before, during and after GR, Dormandy J, Razavi M, Reekers J, Norgren L. An Update on transcatheter aortic valve replacement (TAVR). J Thromb Methods for Revascularization and Expansion of the TASC Lesion Thrombolysis 2015; 39(4): 467–73. Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Sharma A, Lavie CJ, Borer JS, Vallakati, Goel S, Lopez-Jimenez Arterial Disease (TASC II). Vasc Med. 2015 Oct; 20(5): 465–78. F, Arbab-Zadeh A, Mukherjee D, Lazar JM. Meta-analysis of the relation of body mass index to all-cause and cardiovascular Thihalolipavan S, Morin DP. Atrial Fibrillation and Heart Failure: mortality and hospitalization in patients with chronic heart Update 2015. Prog Cardiovasc Dis 2015;126–135. doi: failure. Am J Cardiol 2015 May 15; 115(10): 1428–34. 10.1016/j.pcad.2015.07.004
Sharma A, Thakar S, Lavie CJ, Garg J, Krishnamoorthy P, Sochor Tremmel J. Patel RAG, Bhatt DL, Cilingiroglu M, Pinto DS, O, Arbab-Zadeh A, Lichstein E. Cardiovascular adverse events Dean LS, Grines CL. Commentary on Late Breaking Trials in associated with smoking-cessation pharmacotherapies. Curr Interventional Cardiology at ESC, VIVA TCT, AHA (Fall 2013). Cardiol Rep 2015 Jan; 17(1): 554. Catheter Cardiovasc Interv. 2015 Jan 1; 85(1): 95-103.
Sinha SS, Julien HM, Krim SR, Ijioma NN, Baron SJ, Rock AJ, Turi BC, Codogno JS, Fernandes RA, Sui X, Lavie CJ, Blair SN, Siehr SL, Cullen MW; American College of Cardiology Fellow- Monteiro HL. Accumulation of domain-specific physical activity in-Training Section Leadership Council. COCATS 4: Securing the and presence of hypertension in Brazilian public healthcare Future of Cardiovascular Medicine. J Am Coll Cardiol. 2015. system. J Phys Act Health 2015 Feb 24 [Epub ahead of print]. 65(17): 1907–1914. Ventura HO. Bioethics in Practice: Quantity, but more Sui X, Brown WJ, Lavie CJ, West DS, Pate RR, Payne JP, Blair important, quality of life in heart failure. Ochsner Journal, 2015 SN. Associations between television watching and car riding Fall; 15(3): 216 behaviors and development of depressive symptoms: a prospective study. Mayo Clin Proc 2015 Feb; 90(2): 184–93. Verheye S, Jolicqeur EM, Behan MW, Pettersson T, Sainsbury P, Hill J, Vrolix M, Agostoni P, Engstrom T, Labinaz M, de Silva R, Tafur-Soto JD, White CJ. Renal artery stenosis. Cardiol Clin. Schwartz M, Meyten N, Uren NG, Doucet S, Tanguay JF, Lindsay 2015; 33(1): 59–73. S, Henry TD, White CJ, Edelman ER, Banai S. Efficacy of device to narrow the coronary sinus in refractory angina. N Engl J TASC Steering Committee, Jaff MR, White CJ, Hiatt WR, Med. 2015; 372(6):519-27. Fowkes GR, Dormandy J, Razavi M, Reekers J, Norgren L. An Update on Methods for Revascularization and Expansion Webb JG, Doshi D, Mack MJ, Makkar R, Smith CR, Pichard
CARDIOVASCULAR SERVICES CARDIOVASCULAR of the TASC Lesion Classification to Include Below-the-Knee AD, Kodali S, Kapadia S, Miller DC, Babaliaros V, Thourani V,
| Arteries: A Supplement to the Inter-Society Consensus for Hermann HC, Bodenhamer M, Whisenant BK, Ramee S, the Management of Peripheral Arterial Disease (TASC II). Maniar H Jr., Kereiakes D, Xu K, Jaber WA, Menon V, Tuzcu J Endovasc Ther. 2015 Oct; 22(5): 663–77. EM, Wood D, Svensson LG, Leon MB. A randomized evaluation of the SAPIEN XT Transcatheter Heart Valve System in patients
OUTCOMES with aortic stenosis who are not candidates for surgery. JACC Cardiovasc Interv. 2015; 8(14): 1797–806. OCHSNER
64 Abstracts Angiography to Catheter-Based Angiography with Iintravascular Ultrasound As the Gold-standard. Journal of the American College of Cardiology 03/2015; 65(10):A2049. (2015 American Benjo A, Garcia D, White CJ, Cardoso R, Macedo F, Schob A, College of Cardiology Scientific Sessions, San Diego, CA) El- Hayek G, Nadkarni G, Patel RAG. A Meta-analysis of Multi- vessel Versus Culprit Artery Only PCI in ST-segment Elevation Hanna, Nicholas N., Reilly, John, Patel, Rajan, Dornelles, Myocardial Infarction. Journal of the American College of Adriana, White, Christopher. Determination of Lesion Severity Cardiology 03/2015; 65(10): A1768. (2015 American College in Patients with Peripheral Arterial Disease: A Comparison of Cardiology Scientific Sessions, San Diego, CA) of Computed Tomographic Angiography to Catheter-Based Angiography with Intravascular Ultrasound as the Gold Bober B, Dugas C, Luo Q, Morin D. The Impact of Gender, Standard. J Am Coll Cardiol. 2015 Mar 17 Vol. 65: A507 Body Mass Index and Bra Cup Size on Spect-Mpi Defects Harless A, Rosenthal TM, Morin DP, Khatib S, Abi Samra FM, Bober RM, Dugas C, Luo Q, Morin DP. The Impact of Gender, MD, Bernard ML, Polin GM. Incidence and Predictors of Delayed Body Mass Index, and Bra Cup Size on SPECT-MPI Defects. Permanent Pacemaker Implantation after Surgical Aortic Valve Poster presentation and e-poster, American Society of Nuclear Replacement. Poster Presentation, Heart Rhythm Society Cardiology, 2015. Scientific Sessions, 2015. Chong-Yik R, Bennett AL, Milani RV, Morin DP. Appropriateness Harless A, Rosenthal TM, Morin DP, Khatib S, Abi Samra FM, of Telemetry Monitoring in a General Inpatient Setting. Poster MD, Bernard ML, Polin GM. Incidence and Predictors of Delayed presentation, Louisiana Chapter of ACC, 2015. Permanent Pacemaker Implantation after Surgical Aortic Valve Replacement. Poster presentation, Ochsner Research Day, 2015. Chong-Yik R, Bennett AL, Milani RV, Morin DP. Appropriateness of Telemetry Monitoring in a General Inpatient Setting. Poster Jacobs E, Shah S, Collins T, Ramee S, Gilliland Y. The Use presentation, Ochsner Research Day, 2015. of Speckle Tracking Echo Strain to Predict Recovery of Left Ventricular Function After Transcatheter Aortic Replacement. Chong-Yik R, Bennett AL, Milani RV, Morin DP. Telemetry ACC 2015 San Diego Overuse and Its Economic Implications. Poster presentation, American College of Cardiology Scientific Sessions 2015. Jacobs Evan, Shah Sangeeta, Collins Tyrone, Ramee Stephen, Gilliland Yvonne. The Use of Speckle Training Strain to Predict De Schutter A, Lavie CJ, Jahangir E, Menezes AR, Dinshaw H, Shum Recovery of Left Ventricular Function After Transcatheter Aortic K, Arena R, Milani RV. Nonresponders to cardiac rehabilitation and Valve Replacement. J Am Coll Cardiol. 2015; 65: A295 outcomes. Circulation 2015; 132: a16117. AHA. Kelly Shum, Amber Solivan, Parham Parto, Nichole Polin, Eiman Dugas CM, Bober RM, Morin DP, Jahangir E. Effects of Gender, Jahangir. The 10-year ASCVD Risk amongst women with breast Body Mass Index, and Brassiere Cup Size on Single Photon cancer in a Cardio-oncology Clinic. Ochsner Medical Center Emission Computed Tomography Myocardial Perfusion Imaging. Research Day, May 2015 Poster presentation, Ochsner Research Day, 2015.
Keswani AN, Williams C, Fuloria J, Polin NM, Jahangir E. RESEARCH Hanna N, Reilly J, Patel RAG, Dornelles A, White CJ. Rituximab induced acute ST elevation myocardial infarction. Determination of Lesion Severity in Patients with Peripheral Ochsner Medical Center Research Day, May 2015 Arterial Disease: A Comparison of Computed Tomographic
65 Lee DC, Lavie CJ, Church TS, Sui X, Blair SN. Leisure-time Rosenthal TM, Stahls PF III, Abi Samra FM, Bernard ML, Khatib running and incident type 2 diabetes. American Heart S, Polin GM, Xue JQ, Morin DP. Effect of heart rate correction Association. Epidemiology and Prevention/Lifestyle and on the T-peak to T-end interval’s risk stratification ability. Poster, Cardiometabolic Health Annual Conference. Baltimore, Heart Rhythm Society Scientific Sessions 2015. Maryland, 2015. Rosenthal TM, Stahls PF III, Abi Samra FM, Bernard ML, Khatib Lee DC, Lavie CJ, Church TS, Sui X, Blair SN. Leisure-time S, Polin GM, Xue JQ, Morin DP. Effect of Measurement Method running and mortality in adults with hypertension. American on the T-peak to T-end Interval’s Ability to Risk-Stratify for College of Sports Medicine Annual Meeting. San Diego, Ventricular Tachyarrhythmia and Mortality. Poster presentation, California, 2015. Ochsner Research Day, 2015.
Menezes AR, De Schutter A, Lavie CJ, Milani RV. Impact Rosenthal TM, Stahls PF III, Abi Samra FM, Bernard ML, of depression, anxiety, hostility, and combined psychosocial Khatib S, Polin GM, Xue JQ, Morin DP. T-peak to T-end stress on mortality after cardiac rehabilitation. Louisiana Interval for Prediction of Ventricular Tachyarrhythmia and ACC, October 9, 2015. Mortality in a Primary Prevention Population with Systolic Cardiomyopathy. Oral Presentation, Ochsner Research Day Nanjundappa R, Patel RAG, et al. Outcomes after Prophylactic (Third prize, Ochsner Medical Foundation Resident/Fellow Intra-aortic Balloon Pump Insertion Prior to Elective Surgical Left Research Competition, Dr. Rosenthal), 2015. Ventricular Assist Device Implantation. Journal of the American College of Cardiology 03/2015; 65(10S): A889. (Best Abstract Sharma A, Sharma SK, Garg A, Vallakati A, Stone G, Mukherjee Award. 2015 American College of Cardiology Scientific D, Lavie CJ, Marmur JD. Duration of dual antiplatelet therapy Sessions, San Diego, CA) after various drug eluting implantation. Circulation 2015; 132: A14867. Rogers PA, Hoffman R, Abi Samra FM, Bernard ML, Khatib S, Polin GM, Collins T, Ramee S, Morin DP. Incidence of Pacemaker Sharma A, Vallakati A, Goel S, Lavie C, Kassotis J, Warrier N, Implantation and Paravalvular Aortic Insufficiency After Transcatheter Mukherjee D, Lazar J, Einstein AJ. Relationship of baseline right Aortic Valve Replacement: A Comparison of Three Generations ventricular function with response to cardiac resynchronization of Edwards SAPIEN Valves. Poster presentation, American College therapy. Circulation 2015; 132: A14810. of Cardiology Scientific Sessions, 2015. Sui X, Zhang J, Kokkios PF, Lavie CJ, Lee DC, Church TS, Rosenthal T, Karim S, Abi Samra FM, Bernard ML, Khatib S, Blair SN. Longitudinal patterns of cardiorespiratory fitness can Polin GM, Jahangir E, Bober RM, Morin DP. Positron Emission predict the development of hypertension among men and Tomography Stress Myocardial Blood Flow Predicts Ventricular women. Poster (#70) presented at the American College of
CARDIOVASCULAR SERVICES CARDIOVASCULAR Tachyarrhythmia in Patients with an Implantable Cardioverter- Sports Medicine 62nd annual meeting and sixth World congress
| Defibrillator. Poster presentation, Ochsner Research Day, 2015. on Exercise is Medicine and World Congress on the Basic Science of Exercise Fatigue, San Diego, CA, May 27, 2015. Rosenthal TM, Rogers PA, Thihalolipavan S, Abi Samra FM, Bernard ML, Khatib S, Polin GM, Jahangir E, Bober RM, Morin Swift D, Johannsen NM, Lavie CJ, Berry JD, Earnest CP.
OUTCOMES DP. Positron emission tomography stress myocardial blood The effect of exercise training modality on 30-year CV risk in flow predicts ventricular tachyarrhythmia in primary prevention individuals with type 2 diabetes. March 2015 American Heart ICD patients. Featured poster, Heart Rhythm Society Scientific Association – EPI/Lifestyle Conference, Baltimore, Maryland. Sessions 2015. OCHSNER
66 Swift DL, Johannsen NM, Lavie CJ, Earnest CP, Blair SN. Lavie CJ. The Obesity Paradox – When Thinner Means Sicker The effect of clinically significant weight loss with exercise and Heavier Means Healthier. New York, NY:Hudson Street training on cardiometabolic adaptations. 2015 American Press; 2014 ( paperback published April , 2015.) College of Sports Medicine, San Diego, California. Menezes A, Krim SR, Ventura HO. The established therapies: Todd Rosenthal MBBS, Saima Karim DO, Freddy Abi Samra MD, HF-PEF and HF-REF in: Pharmacologic Trends of Heart Failure. Michael Bernard MD PhD, Sammy Khatib MD, Glenn Polin MD, Springer Publishing (submitted) Eiman Jahangir MD MPH FACC, Robert Bober MD FACC, Daniel P. Morin MD MPH FACC. Positron Emission Tomography Stress White CJ. Atherosclerotic Peripheral Arterial Disease. In: Myocardial Blood Flow Predicts Ventricular Tachyarrhythmia in Goldman L and Schafer AI. Goldman-Cecil Medicine 25th Patients with an Implantable Cardioverter-Defibrillator. ACC 2015 Edition. Philadelphia: Saunders Elsevier. 2015: 497–503.
White CJ. Mesenteric Artery Intervention: Catheter-Based Books/Book Chapters Therapy for Chronic Mesenteric Ischemia. In: Bhatt DL. Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease. Philadelphia: Elsevier. 2015: 331–334. Campbell PT, Krim SR, Ventura HO. Stage C: Patients with symptomatic heart failure in: 4th Edition of Management White CJ. Renal Artery Intervention: Catheter-Based Therapy Complex of CV Problems. Blackwell Publishing (submitted) for Renal Artery Stenosis. In: Bhatt DL. Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease. Church TS, Lavie CJ, Sarznyski MA, Swift DL. Exercise and Philadelphia: Elsevier. 2015: 321–330. lipids. In: Ballantyne CM, ed. Clinical Lipidology: A Companion to Braunwald’s Heart Disease. Philadelphia, PA: Elsevier; 2015: 210–216.
Jenkins James Stephen, Htyte Nay. Diagnostic Cerebral and Peripheral Angiography. In: PanVascular Medicine II (Editor: Peter Lanzer) P. Lanzer, Springer Berlin Heidelberg: 2015, 1177–1223.
Lavie CJ, Alpert MA, Ventura HO. Risks and benefits of weight loss in heart failure. In: Exercise and Rehabilitation in Heart Failure. Editors, Mehra MR and Butler J. Elsevier Publishers. Heart Failure Clin 2015 (11)1: 125–131
Lavie CJ, Wenger NK. Special patient populations: women and elderly. In: Ballantyne CM, ed. Clinical Lipidology: A Companion to Braunwald’s Heart Disease. Philadelphia, PA: Elsevier; 2015: 418–426. RESEARCH
67 Physician Team
Ochsner Medical Center – Interventional Cardiology Ochsner Medical Center – New Orleans John Reilly, MD North Shore Section Head, Interventional Cardiology Consultative Cardiology Vice Chairman, Clinical Affairs, Michael Bennett, MD Patrick Breaux, MD Department of Cardiovascular Disease James Lam, MD Section Head, Consultative Cardiology Director , Cardiovascular CT Glenn Polin, MD Medical Director, Cardiac Step- Program Director, Interventional Down Unit Cardiology Fellowship Program Patrick Delaney, MD Tyrone Collins, MD Ochsner Medical Center – Mark Effron, MD J. Stephen Jenkins, MD West Bank Campus David Elizardi, MD Rajan Patel, MD Gary Rich, MD Stephen Ramee, MD Samuel Ferris, MD Nichole Polin, MD Christopher White, MD Sanjay Dravid, MD Michael Castine, MD Advanced Heart Failure/Transplant Vascular Medicine Hector Ventura, MD Sayf Al-Tabqchali, MD Section Head, Advanced Heart Failure/ Ochsner Medical Center – Kenner Transplantation Noninvasive Cardiology Sapna Desai, MD Michael Cash, MD Jonathan Bonilla, MD Hamang Patel, MD Section Head, Non-Invasive Nakash Grant, MD Stacy Mandras, MD Cardiovascular Imaging Zola N’dandu, MD Clem Eiswirth, MD J. Alberto Bernal, MD Daniel Morin, MD Selim Krim, MD Robert Bober, MD Benjamin Romick, MD Homeyar Dinshaw, MD Electrophysiology Yvonne Gilliland, MD Sammy Khatib, MD Carl “Chip” Lavie, MD Ochsner Medical Center – Vice Chairman, Department Richard Milani, MD Baton Rouge of Cardiology Salima Qamruddin, MD Section Head, Electrophysiology Sangeeta Shah, MD Lei Gao, MD CARDIOVASCULAR SERVICES CARDIOVASCULAR
Program Director, Clinical Cardiac Brian Jones, MD | Electrophysiology Bahij Khuri, MD Freddy Abi-Samra, MD Ochsner Health Center – Covington Douglas Mendoza, MD Daniel Morin, MD Salvador Velazquez, MD Glenn Polin, MD Gerardo Aristimuno, MD Zee Zheng, MD
OUTCOMES Michael Bernard, MD George Isa, MD Michael Bernard, MD Paul Rogers, MD Michael Lecce, MD Freddy Abi-Samra, MD Sammy Khatib, MD Leonardo Orejarena, MD OCHSNER
68 Contact Information and Locations
Baton Rouge Ochsner Health Center – Sherwood Kenner 170 McGehee Dr. Ochsner Medical Center – Baton Rouge, LA 70815 Ochsner Medical Center – Kenner Baton Rouge 225.761.5200 180 W. Esplanade Ave. 17000 Medical Center Dr. Kenner, LA 70065 Baton Rouge, LA 70816 Ochsner Health Center – 504.464.8600 225.752.2470 Summa (Bluebonnet Boulevard) 9001 Summa Ave. Ochsner Health Center – Kenner Ochsner Health Center – Hammond Baton Rouge, LA 70809 200 West Esplanade Ave., Suite 205 16045 Doctors Blvd. 225.761.5200 Kenner, LA 70065 Hammond, LA 70403 504.464.8588 985.543.3664 Greater New Orleans Ochsner Health Center – St. James Ochsner Medical Complex – Iberville Ochsner Medical Center 1645 Lutcher Ave. 25455 Hwy. 1 1514 Jefferson Hwy. Lutcher, LA 70071 Plaquemine, LA 70764 New Orleans, LA 70121 225.258.2037 225.761.5200 504.842.4135 or 866.Ochsner Ochsner Health Center – Ochsner Health Center – Central Ochsner Health Center – Mid-City LaPlace Medical 11424-2 Sullivan Rd. 411 N. Carrollton Ave., Suite 4 735 W. 5th St. Central, LA 70818 New Orleans, LA 70119 LaPlace, LA 70068 225.261.9790 504.842.4135 or 866.Ochsner 985.224.1248
Ochsner Health Center – Ochsner Health Center – Metairie West Bank CONTACT INFORMATION AND LOCATIONS Denham Springs South 2005 Veterans Memorial Blvd. 139 Veterans Blvd. Metairie, LA 70002 Ochsner Health Center – Lapalco Denham Springs, LA 70726 504.842.4168 4225 Lapalco Blvd. 225.761.5200 Marrero, LA 70072 North Shore 504.595.8119 Ochsner Health Center – O’Neal 16777 Medical Center Dr. Ochsner Health Center – Covington Ochsner Medical Center – Baton Rouge, LA 70816 1000 Ochsner Blvd. West Bank Campus 225.754.3278 Covington, LA 70433 2500 Belle Chasse Hwy. 985.875.2828 Gretna, LA 70056 Ochsner Health Center – Prairieville 504.371.9355 16220 Airline Hwy. Ochsner Specialty Health Center One – Prairieville, LA 70769 Slidell 225.744.1111 1850 E. Gause Blvd. Slidell, LA 70461 985.639.3777 69 About Ochsner Health System
Ochsner Health System is Louisiana’s largest non-profit, academic healthcare system. Driven by a mission to Serve, Heal, Lead, Educate and Innovate, coordinated clinical and hospital patient care is provided across the region by Ochsner’s 28 owned, managed and affiliated hospitals and more than 60 health centers. Ochsner cares for patients from all 50 states and more than 80 countries worldwide each year. Ochsner employs 17,000 employees and over 1,000 physicians in over 90 medical specialties and subspecialties and conducts more than 1,000 clinical research studies. Ochsner Health System is proud to be a tobacco-free environment. For more information, please visit ochsner.org and follow us on Twitter and Facebook.
Patient referrals, transfers and consults are critically important. We make it easy Visit us online at ochsner.org for referring providers and their staff. To refer your patient for a clinic appointment, call our Clinic Concierge at 855.312.4190. To initiate a transfer to any Ochsner hospital, call our Regional Referral Center, staffed 24/7 by clinicians, at 855.OHS.LINK (647.5465).
For patients needing to schedule their own appointments, please call 866.OCHSNER (624.7637). CARDIOVASCULAR SERVICES CARDIOVASCULAR
| OUTCOMES OCHSNER
70 Rankings 2015
Healthgrades® awarded Ochsner hospitals a combined total of 29 Five-Star Rankings in 16 categories in 2015, including neurosurgery, total knee replacement, coronary interventional procedures and for treatment of stroke, heart attack and respiratory failure.
U.S. News & World Report ranked Ochsner Medical Center as one of the nation’s top hospitals in six specialties, including ear, nose and throat, gastroenterology & GI surgery, nephrology, neurology & neurosurgery, orthopedics and pulmonology.
CareChex® ranked Ochsner Medical Center as one of the nation’s top hospitals for Medical Excellence in 17 specialties, including #1 for liver transplants, #4 for trauma care and #8 for overall hospital care in 2015. OCHSNER.ORG